AUPH
Price
$11.32
Change
-$0.03 (-0.26%)
Updated
Oct 6 closing price
Capitalization
1.49B
23 days until earnings call
LRMR
Price
$4.81
Change
-$0.06 (-1.23%)
Updated
Oct 6 closing price
Capitalization
411.69M
42 days until earnings call
Interact to see
Advertisement

AUPH vs LRMR

Header iconAUPH vs LRMR Comparison
Open Charts AUPH vs LRMRBanner chart's image
Aurinia Pharmaceuticals
Price$11.32
Change-$0.03 (-0.26%)
Volume$1.45M
Capitalization1.49B
Larimar Therapeutics
Price$4.81
Change-$0.06 (-1.23%)
Volume$3.65M
Capitalization411.69M
AUPH vs LRMR Comparison Chart in %
AUPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AUPH vs. LRMR commentary
Oct 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AUPH is a Buy and LRMR is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 07, 2025
Stock price -- (AUPH: $11.32 vs. LRMR: $4.81)
Brand notoriety: AUPH and LRMR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AUPH: 69% vs. LRMR: 125%
Market capitalization -- AUPH: $1.49B vs. LRMR: $411.69M
AUPH [@Biotechnology] is valued at $1.49B. LRMR’s [@Biotechnology] market capitalization is $411.69M. The market cap for tickers in the [@Biotechnology] industry ranges from $103.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AUPH’s FA Score shows that 0 FA rating(s) are green whileLRMR’s FA Score has 1 green FA rating(s).

  • AUPH’s FA Score: 0 green, 5 red.
  • LRMR’s FA Score: 1 green, 4 red.
According to our system of comparison, LRMR is a better buy in the long-term than AUPH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AUPH’s TA Score shows that 5 TA indicator(s) are bullish while LRMR’s TA Score has 7 bullish TA indicator(s).

  • AUPH’s TA Score: 5 bullish, 3 bearish.
  • LRMR’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, LRMR is a better buy in the short-term than AUPH.

Price Growth

AUPH (@Biotechnology) experienced а +2.35% price change this week, while LRMR (@Biotechnology) price change was +42.31% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.91%. For the same industry, the average monthly price growth was +14.77%, and the average quarterly price growth was +84.62%.

Reported Earning Dates

AUPH is expected to report earnings on Oct 30, 2025.

LRMR is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (+6.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AUPH($1.49B) has a higher market cap than LRMR($412M). AUPH YTD gains are higher at: 26.058 vs. LRMR (24.289). AUPH has higher annual earnings (EBITDA): 86.5M vs. LRMR (-108.21M). AUPH has more cash in the bank: 315M vs. LRMR (139M). LRMR has less debt than AUPH: LRMR (4.61M) vs AUPH (81.8M). AUPH has higher revenues than LRMR: AUPH (260M) vs LRMR (0).
AUPHLRMRAUPH / LRMR
Capitalization1.49B412M362%
EBITDA86.5M-108.21M-80%
Gain YTD26.05824.289107%
P/E Ratio26.33N/A-
Revenue260M0-
Total Cash315M139M227%
Total Debt81.8M4.61M1,773%
FUNDAMENTALS RATINGS
AUPH vs LRMR: Fundamental Ratings
AUPH
LRMR
OUTLOOK RATING
1..100
5715
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
29
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
51100
PRICE GROWTH RATING
1..100
4138
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LRMR's Valuation (29) in the null industry is somewhat better than the same rating for AUPH (73) in the Biotechnology industry. This means that LRMR’s stock grew somewhat faster than AUPH’s over the last 12 months.

LRMR's Profit vs Risk Rating (100) in the null industry is in the same range as AUPH (100) in the Biotechnology industry. This means that LRMR’s stock grew similarly to AUPH’s over the last 12 months.

AUPH's SMR Rating (51) in the Biotechnology industry is somewhat better than the same rating for LRMR (100) in the null industry. This means that AUPH’s stock grew somewhat faster than LRMR’s over the last 12 months.

LRMR's Price Growth Rating (38) in the null industry is in the same range as AUPH (41) in the Biotechnology industry. This means that LRMR’s stock grew similarly to AUPH’s over the last 12 months.

LRMR's P/E Growth Rating (100) in the null industry is in the same range as AUPH (100) in the Biotechnology industry. This means that LRMR’s stock grew similarly to AUPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AUPHLRMR
RSI
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
86%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
84%
Momentum
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
80%
MACD
ODDS (%)
N/A
Bullish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 15 days ago
82%
Bullish Trend 4 days ago
85%
Declines
ODDS (%)
Bearish Trend 7 days ago
82%
Bearish Trend 7 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
AUPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSKFF1.170.10
+9.24%
Talisker Resources Ltd.
ANOYX24.70N/A
N/A
American Century Small Cap Growth Y
NVLPF0.24N/A
N/A
Nova Leap Health Corp.
ERMAY6.67-0.01
-0.15%
Eramet-SLN
SMMYY8.33-0.08
-0.95%
Sumitomo Metal Mining Co., Ltd.

AUPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, AUPH has been loosely correlated with JSPR. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if AUPH jumps, then JSPR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AUPH
1D Price
Change %
AUPH100%
-0.26%
JSPR - AUPH
44%
Loosely correlated
-3.61%
MLTX - AUPH
42%
Loosely correlated
+2.73%
VCYT - AUPH
39%
Loosely correlated
+0.11%
KALA - AUPH
38%
Loosely correlated
-1.30%
LRMR - AUPH
38%
Loosely correlated
-1.23%
More

LRMR and

Correlation & Price change

A.I.dvisor indicates that over the last year, LRMR has been loosely correlated with ARCT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if LRMR jumps, then ARCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LRMR
1D Price
Change %
LRMR100%
-1.23%
ARCT - LRMR
46%
Loosely correlated
-6.87%
MLTX - LRMR
44%
Loosely correlated
+2.73%
TERN - LRMR
44%
Loosely correlated
+2.43%
ACLX - LRMR
44%
Loosely correlated
-0.81%
ATXS - LRMR
43%
Loosely correlated
+2.26%
More